中华结核和呼吸杂志
中華結覈和呼吸雜誌
중화결핵화호흡잡지
Chinese Journal of Tuberculosis and Respiratory Diseases
2015年
5期
366-369
,共4页
林其昌%刘凯雄%刘少滨%林挺岩%赖国祥%洪旭初
林其昌%劉凱雄%劉少濱%林挺巖%賴國祥%洪旭初
림기창%류개웅%류소빈%림정암%뢰국상%홍욱초
抗菌药%肺疾病,慢性阻塞性%急性加重
抗菌藥%肺疾病,慢性阻塞性%急性加重
항균약%폐질병,만성조새성%급성가중
Anti-bacterial agents%Pulmonary disease,chronic obstructive%Acute exacerbation
目的 研究莫西沙星治疗慢性阻塞性肺疾病(慢阻肺)急性加重的疗效和安全性.方法 采用前瞻性、多中心、随机对照方法,收集2011年12月至2013年12月来自福建省21家不同等级医院的慢阻肺急性加重期需抗生素治疗的患者202例.根据电脑编号随机分为2组:(1)莫西沙星治疗组102例,男60例,女42例,年龄为(69.8±6.5)岁,给予莫西沙星注射液400 mg/d静脉滴注,1次/d;(2)对照组100例,男56例,女44例,年龄为(69.6±6.7)岁,给予头孢哌酮/舒巴坦注射液3 g静脉滴注,1次/8 h.评估两组临床疗效、细菌清除率及药物不良反应.两组间率的比较采用x2检验,均数比较采用t检验分析.结果 莫西沙星组临床治疗有效率为90.2％(92/102),对照组临床治疗有效率为88.0％(88/100);莫西沙星组细菌清除率为51.9％(14/27),对照组细菌清除率为48.3％ (14/29),两组临床有效率及细菌清除率比较差异无统计学意义(x2值为0.251和0.072,均P＞0.05);莫西沙星组抗生素使用时间及平均住院天数[(6.7±2.2)和(8.7±2.3)d]比对照组[(8.7±2.4)和(11.7±3.0)d]短,两组比较差异有统计学意义(t值为6.360和7.732,均P＜0.01)).莫西沙星组未发生严重药物不良反应,两组不良反应比较差异无统计学意义(P＞0.05).结论 莫西沙星治疗慢阻肺急性加重的疗效与头孢哌酮/舒巴坦相似,且住院和抗生素使用时间明显缩短,安全性好.
目的 研究莫西沙星治療慢性阻塞性肺疾病(慢阻肺)急性加重的療效和安全性.方法 採用前瞻性、多中心、隨機對照方法,收集2011年12月至2013年12月來自福建省21傢不同等級醫院的慢阻肺急性加重期需抗生素治療的患者202例.根據電腦編號隨機分為2組:(1)莫西沙星治療組102例,男60例,女42例,年齡為(69.8±6.5)歲,給予莫西沙星註射液400 mg/d靜脈滴註,1次/d;(2)對照組100例,男56例,女44例,年齡為(69.6±6.7)歲,給予頭孢哌酮/舒巴坦註射液3 g靜脈滴註,1次/8 h.評估兩組臨床療效、細菌清除率及藥物不良反應.兩組間率的比較採用x2檢驗,均數比較採用t檢驗分析.結果 莫西沙星組臨床治療有效率為90.2％(92/102),對照組臨床治療有效率為88.0％(88/100);莫西沙星組細菌清除率為51.9％(14/27),對照組細菌清除率為48.3％ (14/29),兩組臨床有效率及細菌清除率比較差異無統計學意義(x2值為0.251和0.072,均P＞0.05);莫西沙星組抗生素使用時間及平均住院天數[(6.7±2.2)和(8.7±2.3)d]比對照組[(8.7±2.4)和(11.7±3.0)d]短,兩組比較差異有統計學意義(t值為6.360和7.732,均P＜0.01)).莫西沙星組未髮生嚴重藥物不良反應,兩組不良反應比較差異無統計學意義(P＞0.05).結論 莫西沙星治療慢阻肺急性加重的療效與頭孢哌酮/舒巴坦相似,且住院和抗生素使用時間明顯縮短,安全性好.
목적 연구막서사성치료만성조새성폐질병(만조폐)급성가중적료효화안전성.방법 채용전첨성、다중심、수궤대조방법,수집2011년12월지2013년12월래자복건성21가불동등급의원적만조폐급성가중기수항생소치료적환자202례.근거전뇌편호수궤분위2조:(1)막서사성치료조102례,남60례,녀42례,년령위(69.8±6.5)세,급여막서사성주사액400 mg/d정맥적주,1차/d;(2)대조조100례,남56례,녀44례,년령위(69.6±6.7)세,급여두포고동/서파탄주사액3 g정맥적주,1차/8 h.평고량조림상료효、세균청제솔급약물불량반응.량조간솔적비교채용x2검험,균수비교채용t검험분석.결과 막서사성조림상치료유효솔위90.2％(92/102),대조조림상치료유효솔위88.0％(88/100);막서사성조세균청제솔위51.9％(14/27),대조조세균청제솔위48.3％ (14/29),량조림상유효솔급세균청제솔비교차이무통계학의의(x2치위0.251화0.072,균P＞0.05);막서사성조항생소사용시간급평균주원천수[(6.7±2.2)화(8.7±2.3)d]비대조조[(8.7±2.4)화(11.7±3.0)d]단,량조비교차이유통계학의의(t치위6.360화7.732,균P＜0.01)).막서사성조미발생엄중약물불량반응,량조불량반응비교차이무통계학의의(P＞0.05).결론 막서사성치료만조폐급성가중적료효여두포고동/서파탄상사,차주원화항생소사용시간명현축단,안전성호.
Objective To compare the effectiveness and safety of moxifloxacin and cefoperazonesulbactam therapy in acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods This was a prospective,randomized,multicentre study conducted between December 2011 and December 2012 involving 21 hospitals in Fujian.A total of 202 patients with AECOPD requiring antibiotic therapy were enrolled.Of these patients randomized to either treatments,102 patients [male 60,female 42,(69.8 ±6.5) Y] received moxifloxacin (400 mg qd) and 100 [male 56,female 44,(69.6 ± 6.7) y] received cefoperazone-sulbactam (3.0 q8h).Clinical effectiveness,bacterial eradication and drug safety were evaluated.Results The clinical effectiveness rate was 90.2％ (92/102) in the moxifloxacin group and 88.0％ (88/100)in the cefoperazone-sulbactam group.The bacterial eradication rate was 51.9％ (14/27) and 48.3％ (14/29) in the 2 groups respectively.The differences between groups were not statistically significant in terms of clinical and microbiological effectiveness(x2 =0.251,x2 =0.072,both P ＞ 0.05).The length of hospital stay and antibiotic-days were shorter in the moxifloxacin group [(8.7 ± 2.4) vs (11.7 ± 3.0) d;(6.7 ± 2.2) vs (8.7 ± 2.3) d],the differences being significant between the 2 arms.(t =6.360,t =7.732,P ＜ 0.05).Both drugs were well tolerated with no significant differences in numbers of drug-related adverse events (P ＞ 0.05).Conclusions Moxifloxacin was equivalent to cefoperazonesulbactam therapy for clinical success,bacteriologic eradication and showed superiority over the control group in shortening the length of hospital stay and antibiotic-days.Additionally,the drug safety of moxifloxacin was good.
